Increased survival of children with juvenile systemic lupus erythematosus (jSLE) and improved prognosis have led to a change in the long-term health issues arising for jSLE patients. Preservation of gonadal functioning and fertility are of increasing importance for young adults with jSLE. Events during childhood, such as exposure to alkylating agents, may compromise the reproductive potential. Even in the absence of gonadotoxic therapies, fertility may be decreased through organs specific involvement with jSLE. Strategies to preserve the reproductive potential of girl and boys with jSLE are discussed. Lupus (2007) 16, 593—599.
Hochberg MCUpdating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
2.
Doria A., Iaccarino L., Ghirardello A. et al. Long-term prognosis and causes of death in systemic lupus erythematosus . Am J Med2006; 119: 700—706.
3.
Gonzalez B., Hernandez P., Olguin H. et al. Changes in the survival of patients with systemic lupus erythematosus in childhood: 30 years experience in Chile. Lupus2005; 14: 918—923.
4.
Who.World Health Organization (WHO) for the standardized investigation, diagnosis and management of the infertile men (1st edition). Cambridge University Press, 2000: 1—86.
5.
Hirsh A.Male subfertility. Br Med J2003; 327: 669—672.
6.
Carlier JG SO. Oligarche: the age at first ejaculation. Andrologia1985; 17: 104—106.
7.
Sharpe PJ, Nordheim AWDistribution model of human ovulatory cycles. J Theor Biol1980; 83: 663—673.
8.
Brunner HI, Bishnoi A., Barron AC et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus2006; 15: 198—206.
9.
D'Cruz OJ, Haas GG Jr, Reichlin M.Autoantibodies to decondensed sperm nuclear deoxyribonucleic acid in patients with antisperm antibodies and systemic lupus erythematosus detected by immunofluorescence flow cytometry. Fertil Steril1994; 62: 834—844.
10.
Soares PM, Borba EF, Hallak J., Braga AP, Côrrea AL, Silva CAGonadal function in male systemic erythematosus lupus (SLE). Arthritis Rheum2006; 54(Suppl): S435.
11.
Silva CA, Hallak J., Pasqualotto FF, Barba MF, Saito MI, Kiss MHGonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus. J Rheumatol2002; 29: 2000—2005.
12.
Latta K., von Schnakenburg C., Ehrich JHA meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol2001 ; 16: 271—282.
13.
Anderson D. , Bishop JB, Garner RC, Ostrosky-Wegman P., Selby PBCyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks . Mutat Res1995; 330: 115—181.
14.
Vilarinho ST , Costallat LTEvaluation of the hypothalamic-pituitary-gonadal axis in males with systemic lupus erythematosus. J Rheumatol1998; 25: 1097—1103.
15.
Mok CC, Lau CSProfile of sex hormones in male patients with systemic lupus erythematosus . Lupus2000; 9: 252—257.
16.
Athreya BH, Rafferty JH, Sehgal GS, Lahita RGAdenohypophyseal and sex hormones in pediatric rheumatic diseases . J Rheumatol1993; 20: 725—730.
17.
Howell SJ, Radford JA, Ryder WD, Shalet SMTesticular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol1999; 17: 1493—1498.
18.
Howell SJ, Shalet SMPharmacological protection of the gonads. Med Pediatr Oncol1999; 33: 41—45.
19.
Postovsky S. , Lightman A., Aminpour D., Elhasid R., Peretz M., Arush MWSperm cryopreservation in adolescents with newly diagnosed cancer. Med Pediatr Oncol2003; 40: 355—359.
20.
Kenney LB, Nicholson HS, Brasseux C. et al. Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. A Childrens Cancer Group/National Institutes of Health Report. Cancer1996; 78: 169—176.
21.
Jahnukainen K., Ehmcke J., Soder O., Schlatt S.Clinical potential and putative risks of fertility preservation in children utilizing gonadal tissue or germline stem cells. Pediatr Res2006; 59: 40R—47R.
22.
Agarwal A., Ranganathan P., Kattal N. et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril2004; 81: 342—348.
23.
Ethics Committee of the American Society for Repdroductive Medicine.Fertility preservation and reproduction in cancer patients. Fertil Steril2005; 83: 1622—1628.
24.
Hallak J., Hendin BN, Thomas AJ Jr, Agarwal A.Investigation of fertilizing capacity of cryopreserved spermatozoa from patients with cancer. J Urol1998; 159: 1217—1220.
25.
Ranganathan P., Mahran AM, Hallak J., Agarwal A.Sperm cryopreservation for men with nonmalignant, systemic diseases: a descriptive study. J Androl2002; 23: 71—75.
26.
Metcalf MG, Skidmore DS, Lowry GF, Mackenzie JAIncidence of ovulation in the years after the menarche. J Endocrinol1983; 97: 213—219.
27.
Pasoto SG, Mendonca BB, Bonfa E.Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations . Lupus2002; 11: 175—180.
28.
Silva CA, Leal MM, Leone C. et al. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus2002; 11: 419—425.
29.
Brunner H., Silverman E., To T., Bombardier C., Feldman BMRisk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum2002; 45: 436—444.
30.
Chernyshov VP, Radysh TV, Gura IV, Tatarchuk TP, Khominskaya ZBImmune disorders in women with premature ovarian failure in initial period. Am J Reprod Immunol2001; 46: 220—225.
31.
Tincani A., Nuzzo M., Motta M., Zatti S., Lojacono A., Faden D.Autoimmunity and pregnancy: autoantibodies and pregnancy in rheumatic diseases . Ann N Y Acad Sci2006; 1069: 346—352.
32.
Matsubayashi H., Sugi T., Arai T. et al. IgG-antiphospholipid antibodies in follicular fluid of IVF-ET patients are related to low fertilization rate of their oocytes. Am J Reprod Immunol2006 ; 55: 341—348.
33.
Kutteh WHAutoimmune factors in assisted reproduction. Minerva Ginecol2002; 54: 217—224.
34.
Moncayo R., Moncayo HEA new endocrinological and immunological syndrome in SLE: elevation of human chorionic gonadotropin and of antibodies directed against ovary and endometrium antigens. Lupus1995; 4: 39—45.
35.
Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E.Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus?J Rheumatol1999; 26: 1087—1093.
36.
Chikanza ICNeuroendocrine immune features of pediatric inflammatory rheumatic diseases. Ann N Y Acad Sci1999; 876: 71—80; discussion 80—72.
37.
Cabral de Sousa D., das Chagas Medeiros MM, Trindade Viana VS, Salani Mota RMAnti-corpus luteum antibody and menstrual irregularity in patients with systemic lupus erythematosus and Hashimoto's thyroiditis. Lupus2005; 14: 618—624.
38.
Wheatcroft NJ, Salt C., Milford-Ward A., Cooke ID, Weetman APIdentification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure . Hum Reprod1997; 12: 2617—2622.
39.
Silva CA, Febronio MV et al. Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicenter study. Arthritis Rheum2006; 54: 161.
40.
Ioannidis JP , Katsifis GE, Tzioufas AG, Moutsopoulos HMPredictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus . J Rheumatol2002; 29: 2129—2135.
41.
Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SKRisk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus2004; 13: 569—574.
42.
Medeiros MM , Silveira VA, Menezes AP, Carvalho RCRisk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res2001; 34: 1561—1568.
43.
Langevitz P. , Klein L., Pras M., Many A.The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol1992; 28: 157—158.
44.
Boumpas Dt Ah , Vaughan EM, Yarboro CH, Klippel JH, Balow JERisk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med1993; 119: 366—369.
45.
Baqi N., Moazami S., Singh A., Ahmad H., Balachandra S., Tejani A.Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol1996; 7: 924—929.
46.
Vaidya SJ, Atra A., Bahl S. et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission — long-term follow-up. Bone Marrow Transplant2000; 25: 599—603.
47.
Mok CC, Lau CS, Wong RWRisk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum1998; 41: 831—837.
48.
Kreuser ED, Xiros N., Hetzel WD, Heimpel H.Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol1987; 113: 260—266.
49.
de Medeiros SF, Assi PE, de Medeiros MM.Gonadotrophin dynamics during reproductive life. Int J Gynaecol Obstet2004; 87: 24—28.
50.
Kotake T., Usami M., Sonoda T. et al. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan. Am J Clin Oncol1988; 11(Suppl 2): S108—111.
51.
Sippell WG, Partsch CJ, Hummelink R., Lorenzen F.[Long-term therapy with delayed-action LHRH-antagonist decapeptyl depot in girls with precocious puberty. Results of an international multicenter study] . Gynakologe1991; 24: 108—113.
52.
Lahlou N., Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab2000; 13(Suppl 1): 723—737.
53.
de Brito VN , Latronico AC, Arnhold IJ et al. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child1999 ; 80: 231—234.
54.
Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N.Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod1996; 11: 1620—1626.
55.
Blumenfeld Z., Avivi I., Ritter M., Rowe JMPreservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig1999 ; 6: 229—239.
56.
Slater CA, Liang MH, McCune JW, Christman GM, Laufer MRPreserving ovarian function in patients receiving cyclophosphamide . Lupus1999; 8: 3—10.
57.
Mulligan T. , Iranmanesh A., Veldhuis JDPulsatile iv infusion of recombinant human LH in leuprolide-suppressed men unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. J Clin Endocrinol Metab2001; 86: 5547—5553.
58.
Partsch CJ, Sippell WGTreatment of central precoccious puberty. Best Pract ResEndocrinol2002; 16: 165—189.
59.
Tonini G., Lazzerini M.Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab2000; 13(Suppl 1): 795—803.
60.
Blumenfeld Z., Shapiro D., Shteinberg M., Avivi I., Nahir M.Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus2000; 9: 401—405.
61.
van Leudsen H.Dose response of decapeptyl depot using three dosage regimens in gynecological patients (Study 45 CO2/PR/15). Ferring Internat Report1993; 30 July 1993.
62.
Broekmans FJ , Bernardus RE, Berkhout G., Schoemaker J.Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol Endocrinol1992; 6: 153—161.
63.
Waxman JH, Ahmed R., Smith D. et al. Failure to preserve fertility in patients with Hodgkin's disease . Cancer Chemother Pharmacol1987; 19: 159—162.
64.
Research AfHCPa.Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. Agency for Health Care Policy and Research, January 1999.
65.
Kuhlmann M. , Gartner A., Schindler EM, Regidor PA, Buhler K., Schindler AEUterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy . Gynecol Endocrinol1997; 11: 169—174.
McCune JW, Somers E., Ognenovski V., Christman GMUse of leuprolide acetate for ovarian protection during cyclophosphamide therapy of women with severe SLE: a case control study. Paper presented at American College of Rheumatology, 2001.
68.
Neely EK, Bachrach LK, Hintz RL et al. Bone mineral density during treatment of central precocious puberty. J Pediatr1995; 127: 819—822.
69.
Antoniazzi F., Bertoldo F., Lauriola S. et al. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment. J Clin Endocrinol Metab1999; 84: 1992—1996.
70.
Somers EC, Marder W., Christman GM, Ognenovski V., McCune WJUse of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus . Arthritis Rheum2005; 52: 2761—2767.
71.
Akaboshi S. , Takeshita K.A case of atypical absence seizures induced by leuprolide acetate. Pediatr Neurol2000 ; 23: 266—268.
72.
Kasayama S. , Miyake S., Samejima Y.Transient thyrotoxicosis and hypothyroidism following administration of the GnRH agonist leuprolide acetate. Endocr J2000; 47: 783—785.
Metcalfe W. , Boulton-Jones JMExacerbation of lupus nephritis in association with leuprorelin injection for uterine leiomyoma. Nephrol Dial Transplant1997; 12: 1699—1700.
76.
Casoli P., Tumiati B., La Sala G.Fatal exacerbation of systemic lupus erythematosus after induction of ovulation . J Rheumatol1997; 24: 1639—1640.
77.
Buyon JP, Petri MA, Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med2005; 142: 953—962.
78.
Mok CC, Wong RW, Lau CSOvarian failure and flares of systemic lupus erythematosus. Arthritis Rheum1999; 42: 1274—1280.
79.
Meirow D., Assad G., Dor J., Rabinovici J.The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod2004; 19: 1294—1299.
80.
Finas D., Hornung D., Diedrich K., Schultze-Mosgau A.Cetrorelix in the treatment of female infertility and endometriosis. Expert OpinPharmacother2006; 7: 2155—2168.
Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol2006; 24: 2917—2931.
83.
Donnez J., Dolmans MM, Demylle D. et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet2004; 364: 1405—1410.
